Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis RiskMitja Mitrovič, Nadia Barizzone, Nikolaos A. Patsopoulos et al.|Cell|2018Cited by 172
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis – a review of population-specific evidence from randomized clinical trialsAntonios Bayas, Sven G. Meuth, Monika Christ et al.|Therapeutic Advances in Neurological Disorders|2023Cited by 25
Early Treatment With Intravenous Immunoglobulins and Outcomes of Patients With Anti-IgLON5 DiseaseThomas Grüter, Christian G. Bien, Carles Gaig et al.|JAMA Neurology|2025Cited by 7